Oncology Learning Network: Recent Episodes
HMP Global
On this episode of Blood Bytes, a hematology podcast produced by Oncology Learning Network, Steven Treon, MD, PhD, Director of the Bing Center for Waldenström’s macroglobulinemia at the Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School, Boston, sits down with Christian Buske, MD, Medical Director at the Comprehensive Cancer Center and the Institute of Experimental Cancer Research at the University Ulm, Germany, to discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.
Margherita Rimini, MD, discusses the potential link between BRCAness phenotype and response to platinum-based chemotherapy in cholangiocarcinoma.
Ruth He, MD, discusses findings from a subgroup analysis assessing outcomes by primary tumor location in biliary tract cancer treated with durvalumab.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Robert Jones, MD, University of Glasgow, UK, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following chemotherapy for patients with metastatic urothelial carcinoma who were negative for DNA repair biomarkers
Petros Grivas, MD, from the University of Washington Fred Hutchinson Cancer Research Center, shares results from the TROPHY-U-01 phase 2 trial evaluating the use of sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer by HMP Global
Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.
Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.
Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC.
Carla Casulo, MD, Associate Professor, Wilmot Cancer Institute, University of Rochester, New York, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed follicular lymphoma (FL).
Connie Batlevi, MD, PhD shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class, oral, selective EZH2 inhibitor, for patients with FL.
Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer by HMP Global
Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.
Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.
Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias.
John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.
Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.
Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with daratumumab, presented at the 2021 Annual ASH Meeting.
Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma by HMP Global
Charu Aggarwal, MD, Penn Medicine, Philadelphia, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.
Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.
Ezzat Elhassadi, MD, Consultant Hematologist, University Hospital, Waterford, Ireland, discusses the impact of a p53 alteration in patients with mantle cell lymphoma (MCL); these data were presented at the EHA2021 Virtual Congress.
Aki Morikawa, MD, PhD, The University of Michigan, discusses assessing risk of brain metastasis in HER2+ breast cancer.
Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
Peter Martin, MD, talks about the various treatment patterns and outcomes of US patients with MCL over the past 10 years, the findings of which were presented at the 2021 ASCO Annual Meeting.
Dr Fakih Reviews Upfront Molecular Panel Testing in Metastatic GI Cancers by HMP Global
Holly Pederson, MD, Cleveland Clinic, discusses siscusses ancestrally unbiased polygenic breast cancer risk assessment, presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Dr Shah discusses his story on bispecific anti-CD20, anti-CD19 CAR T cells for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Nakia Spencer, Associate Scientist, MD Anderson Cancer Center, discusses the ongoing clinical trial of asparagine synthetase (ASNS) expression predicting response to the GLS1 inhibitor IPN60090 in ovarian cancer, through selective modulation of redox homeostasis, presented at the 2021 AACR Annual Meeting.
Dr Shitara Discusses Trastuzumab Deruxtecan for Treatment in HER2-Positive Gastric Cancer by HMP Global
Fred Saad, MD, University of Montreal Hospital Center, highlights, "Results from ACIS, a Randomized, Placebo Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate Plus Prednisone Versus Abiraterone in Patients with Chemo-Naive Castration-Resistant Prostate Cancer."
Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and new advancements in treatment of HER2+ gastric cancer.
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)."
Dr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.
In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the significance of the ASCEMBL trial presented at the virtual 2020 ASH Annual Meeting and Exposition, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in chronic myeloid leukemia (CML).
In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the use of asciminib versus bosutinib for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP) previously given ≥2 tyrosine kinase inhibitors (TKIs). These data were presented at the virtual 2020 ASH Annual Meeting and Exposition.
In this video, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
Dr Leonard Shares Highlights to Expect at the 2020 Leukemia, Lymphoma & Myeloma Congress by HMP Global
Abhishek Maiti, MD, Talks 10-Day Decitabine Plus Venetoclax for Intensive Chemo–Ineligible AML by HMP Global
Abdul Rahman Jazieh, MD, MPH, National Guard Health Affairs, Riyadh, Saudi Arabia, discusses a study on the presence of ALK+ NSCLC in the Middle East and North Africa, presented at the ESMO 2020 Virtual Congress.
Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent data comparing the American Standard versus European Standard for treatment of Ewing sarcoma.
In an interview with Oncology Learning Network, Udai Banerji, MD, NIHR Professor of Molecular Cancer Pharmacology, The Institute of Cancer Research, London, United Kingdom, discussed the findings and clinical significance of a phase 1 trial evaluating the use of VS-6766, a RAF/MEK inhibitor, plus defactinib, a FAK inhibitor, in patients with KRAS-mutant ovarian cancer.
Veena Shankaran, MD, MS, Discusses Financial Hardships in Patients With Metastatic CRC by HMP Global
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress by HMP Global
Christopher Crane, MD, Discusses Benefits of Long-Course Vs Short-Course RT for Rectal Cancer by HMP Global
Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML by HMP Global
Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.
Shirish Gadgeel, MD, Discusses Follow-Up Results of Pembrolizumab with Chemotherapy for NSCLC by HMP Global
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance (COA) discusses how, in the face of the COVID-19 pandemic, COA is standing strong and readjusting to cater to the needs of community oncologists nationwide.
In this inaugural episode of Sarcoma Sound Bites with Brian and Bob, an Oncology Learning Network Podcast, join Brian Van Tine, MD, PhD, Sarcoma Program Director, Washington University, and Robert “Bob” Maki, MD, PhD, Northwell Health Cancer Center Institute, New York, as they discuss the challenges of treating tenosynovial giant cell tumors (TGCTs), and how the treatment landscape for TGCT has evolved in recent years.
Joshua M. Bauml, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, shares first-hand insight on the management of patients with lung cancer during the COVID-19 pandemic.
In an interview with Oncology Learning Network, Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, talks about the clinical significance and findings of the SWOG S0307 trial.
In an interview with Oncology Learning Network, Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, discusses ways that healthcare providers can encourage patient enrollment in cancer clinical trials.
Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, discusses findings from the SWOG S0307 trial, which looked at the occurrence of fractures in patients with breast cancer receiving high-dose bisphosphonates to prevent metastases.
Michiel Van de Sande, MD, Discusses Multidisciplinary Approach to Treating TGCT by HMP Global
Post-Transplant TKI Salvage Therapy Provides Significant Survival Benefit Following Relapse in CML by HMP Global
In an interview with Oncology Learning Network, Randall A. Oyer, MD, Association of Community Cancer Centers (ACCC) President, discusses the basis and goal of his presidency theme, entitled “Community Oncology Can Close the Gap in Cancer Research.”
In an interview with Oncology Learning Network, Kevin Kalinsky, MD, MS, Herbert Irving Associate Professor of Medicine, NewYork-Presbyterian Hospital/Columbia University Medical Center, discussed why gene profiling plays such an important role in the management of patients with early-stage breast cancer.
Joel Randolph Hecht, MD, David Geffen School of Medicine, University of California Los Angeles, shares findings from the SEQUOIA clinical trial of GEM-refractory pancreatic adenocarcinoma, an overview of recent studies and therapy options for metastatic pancreatic cancer, and what he believes may be the way forward to improve treatment outcomes in this patient population.
Front-Line Ibrutinib Plus Venetoclax Effective for CLL Irrespective of Patient Age by HMP Global
In an interview with Oncology Learning Network, Michelle Melisko, MD, University of California San Francisco, and Melissa Bourestom, Dignitana, discussed the background, benefits, and future potential of the DigniCap Scalp Cooling System, which minimizes hair loss from certain chemotherapy treatments in patients with cancer.
Acalabrutinib Alone or in Combination With Obinutuzumab Improves PFS in Treatment-Naïve CLL by HMP Global
Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia by HMP Global
Dr Pegram, Associate Director for Clinical Research, Stanford Comprehensive Cancer Institute, Palo Alto, California, spoke with Oncology Learning Network about the basis, findings, and clinical significance of the HER2CLIMB clinical trial examining the use of tucatinib therapy in patients with HER2-positive breast cancer.
Recapping a late-breaking abstract from ASCO 2019, Dr Abou-Alfa discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer.Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer as of December 30, 2019.
Dawn Hershman, MD, MS, Professor of Medicine and Epidemiology at Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, discusses how the cost of breast cancer treatment is directly associated with rates of adherence, and explains why financial factors matter in treatment decisions.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the benefits of clinical trial participation for patients with cancer.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Dr Modi discusses the basis, clinical significance, and findings of the DESTINY-Breast04 trial of DS-8201a therapy for HER2-low breast cancer.
Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, spoke with Oncology Learning Network about data that was presented regarding the use of DS-8201a in the treatment of HER2-positive breast cancer.
Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about advancements made in the treatment of patients with early stage, HER2-positive breast cancer.
Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the HER2CLIMB study and the promising role of tucatinib in the treatment of metastatic, HER2-positive breast cancer.
Jonathan Trent, MD, PhD, Professor and Associate Director for Clinical Research, Sylvester Comprehensive Cancer Center, University of Miami, Florida discusses the evolution of the current treatment landscape for tenosynovial giant cell tumors.
Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors by HMP Global
Niraparib After First-Line Chemotherapy New Standard of Care for Advanced Ovarian Cancer by HMP Global
Amer Zeidan, MBBS, MHS, Yale University, discusses diagnosis and treatment of Myelodysplastic Syndrome(MDS)at 2019 ASH Meeting on Hematologic Malignancies
Matthew Seymour, MD, discusses the FOxTROT trial that supports preoperative chemotherapy as a treatment with multiple, clear benefits for patients with colon cancer.
Sara A. Hurvitz, MD, University of California-Los Angeles Jonsson Comprehensive Cancer Center, discusses the background, findings, and clinical significance of the MONALEESA 7 trial, the findings of which were presented at the 2019 ASCO Annual Meeting.
Earlier Daratumamab Use Feasible for Relapsed/Refractory Multiple Myeloma by HMP Global
Matthew B. Schabath, PhD, discusses the results of his team’s national survey, which was conducted to identify potential gaps in attitudes, knowledge, and institutional practices toward LGBTQ patients with cancer.
Daunorubicin Decreases Long-Term Cardiomyopathy Risk in Childhood Cancer Survivors by HMP Global
Patient Characteristics to Consider for Use of Chemotherapy for Soft-Tissue Sarcoma by HMP Global
Are Existing Data Reliable Enough to Support Using Chemo for Soft-Tissue Sarcoma? by HMP Global
Enzalutamide–ADT Combo significantly Improves PFS in Metastatic Hormone-Sensitive Prostate Cancer by HMP Global
“Spectacular” Trial Results Establish New Standard of Care for Advanced Kidney Cancer by HMP Global
Tivozanib Shows Promise Over Sorafenib in Patients With Advanced, Treatment-Refractory RCC by HMP Global
Survival Benefits of PARP Inhibitors in Metastatic CRPC Favor BRCA1/2 Over ATM Mutations by HMP Global
Apalutamide Significantly Delays Metastasis in SPARTAN Trial of Nonmetastatic CRPC by HMP Global
New Advances in Research Pave the Way for the Treatment of Nonclear Cell RCC by HMP Global
Round 3: The Use of Adjuvant And Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma by HMP Global
Round 2: The Use of Adjuvant And Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma by HMP Global
CLL Novel Therapy Patterns, Dosing, and Sequencing: Results of the informCLL Real-World Registry by HMP Global
Gemtuzumab Ozogamicin a Safe, Tolerable Option for Patients With Relapsed/Refractory AML by HMP Global
Early Results Show Promise With Venetoclax-Idasanutlin Combo for Relapsed/Refractory AML by HMP Global
Extended Decitabine Dosing Schedule Provides No Benefit Over Shorter Regimen in Newly Diagnosed AML by HMP Global
Round 1: The Use of Adjuvant And Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma by HMP Global
Introduction: The Use of Adjuvant/ Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma by HMP Global
Cost of Cancer Care in the Outpatient vs Community Oncology Setting - Lucio Gordon by HMP Global
The Future of CML Treatment: An Interview With Gabriela Hobbs, MD - Part 3 by HMP Global
Jonathan Friedberg, MD, Discusses The Future of Treatment for Aggressive Lymphomas - Part III by HMP Global
John Leonard, MD, Discusses the Evolving Treatment Landscape for Mantle Cell Lymphoma - Part I by HMP Global
Salvage Therapies for CML: An Interview With Gabriela Hobbs, MD - Part II by HMP Global
Jonathan Friedberg, MD - Treatment for Aggressive Lymphoma and Clinical Implications - Part II by HMP Global
John Leonard, MD - Future Outlook of Mantle Cell Lymphoma Treatment - Part III by HMP Global
John Leonard, MD - Mantle Cell Lymphoma And Indolent Mantle Cell Lymphoma - Part II by HMP Global
John Leonard, MD - Future Landscape Of FL Therapy, And Managing Survivors Of FL - Part III by HMP Global
John Leonard, MD - The Evolving Treatment Landscape for Follicular Lymphoma - Part I by HMP Global
Dr. Gail Roboz - Clinical Trials and the Future of Treatment in AML – Part III by HMP Global
Dr. Gail Roboz - Using Drugs Newly Approved by the FDA to Treat AML - Part II by HMP Global
Dr. Jonathan Friedberg - Barriers to Care in Aggressive Lymphoma - Part 1 by HMP Global
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population by HMP Global